PMID- 20920042
OWN - NLM
STAT- MEDLINE
DCOM- 20110602
LR  - 20220321
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 12
IP  - 10
DP  - 2010 Oct
TI  - Four weeks administration of Liraglutide improves memory and learning as well as 
      glycaemic control in mice with high fat dietary-induced obesity and insulin 
      resistance.
PG  - 891-9
LID - 10.1111/j.1463-1326.2010.01259.x [doi]
AB  - AIM: Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) mimetic which 
      is a treatment option for type 2 diabetes. GLP-1 peptides, including Liraglutide, 
      cross the blood-brain barrier and may additionally act to improve brain function. 
      The present study tested the hypothesis that, in addition to its 
      antihyperglycaemic actions, peripheral administration of Liraglutide exerts 
      positive actions on cognitive function in mice with high fat dietary-induced 
      obesity and insulin resistance. METHODS: Young Swiss TO mice maintained on high 
      fat diet for 20 weeks received twice-daily injections of Liraglutide (200 microg/kg 
      bw; sc) or saline vehicle over 28 days. An additional group of mice on standard 
      diet received twice-daily saline injections. Energy intake, bodyweight, 
      non-fasting plasma glucose and insulin concentrations were monitored at regular 
      intervals. Glucose tolerance, open field assessment, object recognition testing 
      and electrophysiological long-term potentiation (LTP) were performed at 
      termination of the study. RESULTS: Liraglutide treatment resulted in significant 
      time-dependent reduction in bodyweight and energy intake, whilst improving 
      non-fasting glucose and normalizing glucose tolerance. Although Liraglutide did 
      not alter general behaviour, treated mice exhibited marked increase in 
      recognition index (RI) during object recognition testing, indicative of enhanced 
      learning and memory ability. Furthermore, Liraglutide rescued the deleterious 
      effects of high fat diet on hippocampal LTP of neurotransmission following both 
      chronic and direct intracerebroventricular (icv) administration. CONCLUSION: 
      Liraglutide administered peripherally not only improves metabolic parameters but 
      exerts additional beneficial effects on cognitive function and hippocampal 
      synaptic plasticity. Whether therapy with GLP-1 mimetics has similar effects in 
      humans with type 2 diabetes needs to be established.
CI  - (c) 2010 Blackwell Publishing Ltd.
FAU - Porter, D W
AU  - Porter DW
AD  - The SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, 
      University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK.
FAU - Kerr, B D
AU  - Kerr BD
FAU - Flatt, P R
AU  - Flatt PR
FAU - Holscher, C
AU  - Holscher C
FAU - Gault, V A
AU  - Gault VA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Blood Glucose/*drug effects
MH  - Cognition/*drug effects/physiology
MH  - Diabetes Mellitus, Type 2
MH  - Glucagon-Like Peptide 1/administration & dosage/*analogs & derivatives
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin Resistance/physiology
MH  - Liraglutide
MH  - Male
MH  - Memory/*drug effects/physiology
MH  - Mice
MH  - Obesity/*drug therapy
EDAT- 2010/10/06 06:00
MHDA- 2011/06/03 06:00
CRDT- 2010/10/06 06:00
PHST- 2010/10/06 06:00 [entrez]
PHST- 2010/10/06 06:00 [pubmed]
PHST- 2011/06/03 06:00 [medline]
AID - 10.1111/j.1463-1326.2010.01259.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2010 Oct;12(10):891-9. doi: 
      10.1111/j.1463-1326.2010.01259.x.